Related Experiment Video
Updated: Jun 22, 2026
05:18
A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes
Published on: February 17, 2023
Streptozotocin, type I diabetes severity and bone
Katherine Motyl1, Laura R McCabe
1Departments of Physiology and Radiology, Biomedical Imaging Research Center, Michigan State University, 2201 Biomedical Physical Science Bldg., East Lansing, MI 48824 USA.
Biological Procedures Online
|June 5, 2009
Summary
Type I diabetes causes bone loss in adults. The multiple low-dose streptozotocin (STZ) mouse model mimics human bone pathology, offering a valuable tool for studying diabetes-related bone loss mechanisms.
Area of Science:
- Endocrinology
- Metabolic Bone Disease
- Pharmacology
Background:
- Type I diabetes (T1D) is associated with significant bone loss and increased fracture risk in adults.
- Understanding the molecular mechanisms of T1D-induced bone pathology is crucial for therapeutic development.
- Animal models are essential for studying the systemic and metabolic complexities of T1D bone disease.
Purpose of the Study:
- To evaluate the dose-dependent effects of streptozotocin (STZ) on disease severity and bone pathology in a T1D mouse model.
- To compare the STZ-induced T1D mouse model with spontaneous models and human T1D bone pathology.
- To investigate the potential role of osteoclast activity in severe T1D bone loss.
Main Methods:
- Administration of multiple low doses of streptozotocin (STZ) (40 or 60 mg/kg) to induce type I diabetes in mice.
- Assessment of bone parameters including bone volume, mineral apposition rate, and osteocalcin levels.
- Analysis of bone marrow adiposity and gene expression (aP2, osteocalcin, cathepsin K, RANKL/OPG ratio).
- Evaluation of kidney and liver toxicity.
Main Results:
- Both low and high doses of STZ induced bone pathologies similar to spontaneous T1D models and humans, decreasing bone volume and mineral apposition rate.
- STZ treatment increased bone marrow adiposity and aP2 expression.
- High-dose STZ resulted in more rapid hyperglycemia, greater body mass and fat pad mass changes, and increased osteoclast-related gene expression (cathepsin K, RANKL/OPG ratio), suggesting increased osteoclast activity.
- High-dose STZ also induced mild liver inflammation.
Conclusions:
- The multiple low-dose STZ mouse model effectively replicates the bone phenotype observed in spontaneous T1D models and humans.
- This model exhibits low toxicity and is a useful tool for investigating the mechanisms underlying T1D-related bone loss.
- Severe diabetes may enhance osteoclast activity, potentially explaining disparities in previous research findings.
Related Concept Videos
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:19Type I Diabetes III: Clinical Manifestations
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
01:12Type I Diabetes I: Introduction
Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...